Nivolumab for malignant transformation of ovarian mature cystic teratoma

MLA

70868075, et al. Nivolumab for Malignant Transformation of Ovarian Mature Cystic Teratoma. 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1458649252&authtype=sso&custid=ns315887.

APA

70868075, 70432416, 70893791, 70851012, 20898077, 80779158, 30535836, 80378736, 00335283, 40360698, Yoshimura, K., Yamanoi, K., Kanai, M., Okunomiya, A., Sagae, Y., Sunada, M., Taki, M., Ukita, M., Chigusa, Y., … Mandai, M. (2022). Nivolumab for malignant transformation of ovarian mature cystic teratoma.

Chicago

70868075, 70432416, 70893791, 70851012, 20898077, 80779158, 30535836, et al. 2022. “Nivolumab for Malignant Transformation of Ovarian Mature Cystic Teratoma.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1458649252&authtype=sso&custid=ns315887.